International Journal of Diabetes Mellitus
Volume 2, Issue 2 , Pages 110-113 , August 2010

Safety and efficacy of switching to biphasic insulin aspart 30/70 (BIAsp 30) under the routine diabetic care in patients with type 2 diabetes: The IMPROVE™ observational study in the Gulf region

  • Saied Khader

      Affiliations

    • Department of Internal Medicine, Suliman Al Habib Center, Riyadh, Saudi Arabia
    • Corresponding Author InformationCorresponding author.
    • ,
  • Waleed AbdelFattah

      Affiliations

    • Department of Medical, NovoNordisk Gulf, Riyadh, Saudi Arabia
    • ,
  • Abdulqawi Almansari

      Affiliations

    • Department of Internal Medicine, Erfan General Hospital, Jeddah, Saudi Arabia
    • ,
  • Nabil K. Elnnagar

      Affiliations

    • Diabetes Center, Hai Aljamea Hospital, Jeddah, Saudi Arabia

Received 21 January 2010 ,Accepted 3 May 2010.

References 

  1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2007;30(Suppl. 1):S42–S47.
  2. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care. 2002;25:275–278
  3. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39:1577–1583
  4. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe. Lancet 1999;354:617–21.
  5. Garber AJ, Ligthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for type 2 diabetes: analogue or human?. Diabetes Obes Metab. 2007;9:630–639
  6. Rolla AR, Rakel RE. Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues. Clin Ther. 2005;27:1113–1125
  7. Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1–2–3 study). Diabetes Obes Metab. 2006;8:58–66
  8. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260–265
  9. Kann PH, Wascher T, Zackova V, Moeller J, Medding J, Szocs A, et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes. 2006;114:527–532
  10. Franek E, Kalra S, Pesic M, Smahelova A, Thomsen H, Strojek K. Once daily initiation with biphasic insulin aspart 30 (BIAsp 30) versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs – a randomized controlled trial. Diabetologia. 2009;25(12):2887–2894
  11. Valensi P, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, et al. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Int J Clin Pract. 2009;63:522–531
  12. McGill JB. Selecting among ADA/EASD tier 1 and tier 2 treatment options. J Fam Pract. 2009;58:S26–34
  13. Ligthelm RJ, Borzi V, Gumprecht J, Kawamori R, Wenying Y, Valensi P. Importance of observational studies in clinical practice. Clin Ther. 2007;29:1284–1292
  14. Gough S. Post-marketing surveillance: a UK/European perspective. Curr Med Res Opin. 2005;21:565–570
  15. Valensi P, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, et al. The IMPROVE study – a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Pract. 2008;62:1809–1819
  16. Gumprecht J, Benroubi M, Borzi V, Kawamori R, Shaban J, Shah S, et al. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study. Int J Clin Pract. 2009;63:966–972
  17. Amuna P, Zotor FB. Epidemiological and nutrition transition in developing countries: impact on human health and development. Proc Nutr Soc. 2008;67:82–90
  18. Guy Geoffrey W, Nunn Alistair VW, Thomas Louise E, Bell Jimmy D. Obesity, diabetes and longevity in the Gulf: is there a Gulf Metabolic Syndrome?. Int J Diabetes Mellitus. 2009;1:43–54

PII: S1877-5934(10)00023-8

doi: 10.1016/j.ijdm.2010.05.001

International Journal of Diabetes Mellitus
Volume 2, Issue 2 , Pages 110-113 , August 2010

Article Tools

* Image Usage & Resolution